Top View
- PDL)/Non-Preferred Drug List (NPDL
- Endothelin ETA Receptor Blockade, by Activating ETB Receptors, Increases Vascular Permeability and Induces Exaggerated Fluid Retention S
- Advanced Control Specialty Formulary® Is a Guide Within Select Therapeutic Categories for Clients, Plan Members and Health Care Providers
- E-Binder March 2021
- Distinct ETA Receptor Binding Mode of Macitentan As Determined by Site Directed Mutagenesis
- NEW--Npf-MASTER LIST.Xlsx
- Lemborexant (Dayvigo™) New Drug Update
- (12) United States Patent (10) Patent No.: US 8,664,390 B2 Gaitonde Et Al
- Sitaxsentan Proves Effective in Pulmonary Arterial Hypertension
- Blue Cross and Blue Shield October 2019 Multi-Tier Basic Drug List I How to Use This List Generic Drugs Are Shown in Lower-Case Boldface Type
- Lemborexant (Dayvigo®) FDA Approved December 2019 (Eisai Inc); Schedule IV Controlled Substance
- Medicaid Health Plan Common Formulary
- Final Decisions and Reasons for Decisions by Delegates of the Secretary to the Department of Health
- FEP 5 Tier Rx Drug Formulary (607) Standard Option
- Provider Memorandum Dated August 26, 2020
- TRACLEER (Bosentan)
- Endothelin Receptor Antagonists (Eras) Annual Review Date: Tracleer (Bosentan) 1/21/2021 Letairis (Ambrisentan) Opsumit (Macitentan) Last Revised Date: 2/18/2021
- Sitaxentan-Related Acute Liver Failure in a Patient with Pulmonary Arterial Hypertension
- 2021 Aetna Specialty Drug List
- Wednesday, April 13, 2016 4 P.M
- Blue Cross Blue Shield of Wyoming Standard Drug List Updates April 2018
- Bosentan Reverses the Pro-Fibrotic Phenotype of Systemic Sclerosis Dermal Fibroblasts Via Increasing DNA Binding Ability of Tran
- CVS Caremark® Value Formulary Effective As of 07/01/2021
- 204410Orig1s000
- Short-Term Endothelin Receptor Blockade with Tezosentan Has Both Immediate and Long-Term Beneficial Effects in Rats with Myocard
- FEP 5 Tier Managed Rx Drug Formulary (807) Basic Option
- P&T Committee Meeting Minutes GHP Family November 21
- North Dakota Department of Human Services North Dakota Medicaid Preferred Drug List with Prior Authorization Criteria Effective
- Pulmonary Arterial Hypertension EOCCO POLICY
- The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
- Interactions of Oral Contraceptives and Seizure Medications to Drugs
- Florida Medicaid Brand Drug Preferred List*
- Performance Drug List - Standard Control
- Proposed Formulary Changes Kentucky Medicaid Effective 7/1/2017
- Simultaneous LC-MS Analysis of Plasma Concentrations of Sildenafil, Tadalafil, Bosentan, Ambrisentan, and Macitentan in Patients with Pulmonary Arterial Hypertension
- 2021 Formulary Kaiser Permanente a TRICARE® Prime Option
- A Network Meta-Analysis for Safety of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension
- New Mesh Headings for 2019 Listed in Alphabetical Order with Heading, Scope Note, Annotation (AN), and Tree Locations
- 2021 3-Tier Covered Drugs
- Third Quarter 2017
- Glycemic Control of Diabetes Mellitus Stanford Coordinated Care
- Background Bosentan and Ambrisentan, Endothelin Receptor
- Full Text (PDF)
- 2021 NATIONAL EX FORMULARY the Following Is a List of the Most Commonly Prescribed Brand and Generic Medications
- 2020 List of Covered Drugs (Formulary)
- New Drugs Launched in the UK and Degree of Innovativeness by Year, 2001 to 2012
- Cigna Legacy (Standard) 4-Tier Prescription Drug List
- THELIN® (Sitaxsentan Sodium) from the Market Due to Sitaxsentan Sodium Concerns About Hepatotoxicity